-
Something wrong with this record ?
Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
J. Pospiskova, L. Smolej, D. Belada, M. Simkovic, M. Motyckova, A. Sykorova, P. Stepankova, P. Zak,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
PROGRES Q40/08
Univerzita Karlova v Praze - International
NLK
BioMedCentral
from 2006-01-12
BioMedCentral Open Access
from 2006
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
Springer Nature OA/Free Journals
from 2006-12-01
- MeSH
- Chylothorax drug therapy radiotherapy therapy MeSH
- Thoracic Duct drug effects radiation effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Leukemia, Lymphoid drug therapy radiotherapy therapy MeSH
- Lymphoproliferative Disorders drug therapy radiotherapy therapy MeSH
- Lymphoma, Non-Hodgkin drug therapy radiotherapy therapy MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Chylothorax is a rare condition which can be associated with malignant lymphoproliferative disorders (LPDs). We retrospectively analyzed the results of the conservative treatment of 10 patients with persistent non-traumatic malignant chylothorax. RESULTS: Conservative treatment lead to a decline of chylothorax after mean of 66 days and consisted of the treatment of the underlying disease and of simultaneous long-term supportive care (drainage of the thoracic cavity, dietary measures and nutrition management). In most cases (80%), chylothorax disappeared only after a successful therapeutic response of the underlying disease. Low-dose radiotherapy had very good effects in two patients. CONCLUSION: Conservative treatment of malignant chylothorax can be considered a suitable method. Based on our results, successful treatment of the lymphoproliferative disorder seems to be a very important factor for the disappearance of chylothorax.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19027922
- 003
- CZ-PrNML
- 005
- 20190815105524.0
- 007
- ta
- 008
- 190813s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13023-018-0991-3 $2 doi
- 035 __
- $a (PubMed)30626415
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pospiskova, Jana $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic.
- 245 10
- $a Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders / $c J. Pospiskova, L. Smolej, D. Belada, M. Simkovic, M. Motyckova, A. Sykorova, P. Stepankova, P. Zak,
- 520 9_
- $a BACKGROUND: Chylothorax is a rare condition which can be associated with malignant lymphoproliferative disorders (LPDs). We retrospectively analyzed the results of the conservative treatment of 10 patients with persistent non-traumatic malignant chylothorax. RESULTS: Conservative treatment lead to a decline of chylothorax after mean of 66 days and consisted of the treatment of the underlying disease and of simultaneous long-term supportive care (drainage of the thoracic cavity, dietary measures and nutrition management). In most cases (80%), chylothorax disappeared only after a successful therapeutic response of the underlying disease. Low-dose radiotherapy had very good effects in two patients. CONCLUSION: Conservative treatment of malignant chylothorax can be considered a suitable method. Based on our results, successful treatment of the lymphoproliferative disorder seems to be a very important factor for the disappearance of chylothorax.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a chylotorax $x farmakoterapie $x radioterapie $x terapie $7 D002916
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfoidní leukemie $x farmakoterapie $x radioterapie $x terapie $7 D007945
- 650 _2
- $a nehodgkinský lymfom $x farmakoterapie $x radioterapie $x terapie $7 D008228
- 650 _2
- $a lymfoproliferativní nemoci $x farmakoterapie $x radioterapie $x terapie $7 D008232
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a ductus thoracicus $x účinky léků $x účinky záření $7 D013897
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Smolej, Lukas $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic. Faculty of Medicine in Hradec Králové, Charles University Prague, Hradec Kralove, Czech Republic.
- 700 1_
- $a Belada, David $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic. Faculty of Medicine in Hradec Králové, Charles University Prague, Hradec Kralove, Czech Republic.
- 700 1_
- $a Simkovic, Martin $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic. Faculty of Medicine in Hradec Králové, Charles University Prague, Hradec Kralove, Czech Republic.
- 700 1_
- $a Motyckova, Monika $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic. Faculty of Medicine in Hradec Králové, Charles University Prague, Hradec Kralove, Czech Republic.
- 700 1_
- $a Sykorova, Alice $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic.
- 700 1_
- $a Stepankova, Pavla $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic.
- 700 1_
- $a Zak, Pavel $u 4th Department of Internal Medicine - Hematology, University Hospital, Sokolska Street 581, 5005, Hradec Kralove, Czech Republic. pavel.zak@fnhk.cz. Faculty of Medicine in Hradec Králové, Charles University Prague, Hradec Kralove, Czech Republic. pavel.zak@fnhk.cz.
- 773 0_
- $w MED00165365 $t Orphanet journal of rare diseases $x 1750-1172 $g Roč. 14, č. 1 (2019), s. 9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30626415 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190815105752 $b ABA008
- 999 __
- $a ok $b bmc $g 1433071 $s 1066382
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 14 $c 1 $d 9 $e 20190109 $i 1750-1172 $m Orphanet journal of rare diseases $n Orphanet J Rare Dis $x MED00165365
- GRA __
- $a PROGRES Q40/08 $p Univerzita Karlova v Praze $2 International
- LZP __
- $a Pubmed-20190813
